Replication Inhibitors Modulate Instability of an Expanded Trinucleotide Repeat at the Myotonic Dystrophy Type 1 Disease Locus in Human Cells  by Yang, Zhi et al.
Am. J. Hum. Genet. 73:1092–1105, 2003
1092
Replication Inhibitors Modulate Instability of an Expanded Trinucleotide
Repeat at the Myotonic Dystrophy Type 1 Disease Locus in Human Cells
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1Program of Genetics and Genomic Biology, The Hospital for Sick Children, 2Department of Molecular and Medical Genetics, University of
Toronto, and 3University Health Network, Toronto
Gene-specific CTG/CAG repeat expansion is associated with at least 14 human diseases, including myotonic dys-
trophy type 1 (DM1). Most of our understanding of trinucleotide instability is from nonhuman models, which
have presented mixed results, supporting replication errors or processes independent of cell division as causes.
Nevertheless, the mechanism occurring at the disease loci in patient cells is poorly understood. Using primary
fibroblasts derived from a fetus with DM1, we have shown that spontaneous expansion of the diseased (CTG)216
allele occurred in proliferating cells but not in quiescent cells. Expansions were “synchronous,” with mutation
frequencies approaching 100%. Furthermore, cells were treated with agents known to alter DNA synthesis but not
to directly damage DNA. Inhibiting replication initiation with mimosine had no effect upon instability. Inhibiting
both leading- and lagging-strand synthesis with aphidicolin or blocking only lagging strand synthesis with emetine
significantly enhanced CTG expansions. It was striking that only the expanded DM1 allele was altered, leaving
the normal allele, (CTG)12, and other repeat loci unaffected. Standard and small-pool polymerase chain reaction
revealed that inhibitors enhanced the magnitude of short expansions in most cells threefold, whereas 11%–25%
of cells experienced gains of 122–170 repeats, to sizes of (CTG)338–(CTG)386. Similar results were observed for an
adult DM1 cell line. Our results support a role for the perturbation of replication fork dynamics in DM1 CTG
expansions within patient fibroblasts. This is the first report that repeat-length alterations specific to a disease allele
can be modulated by exogenously added compounds.
Introduction
The unstable expansion of gene-specific repeat sequences
is the causative mutation responsible for at least 33 hu-
man diseases. Fourteen diseases, including myotonic dys-
trophy type 1 (DM1 [MIM 160900]), Huntington dis-
ease (HD), spinocerebellar ataxia type 1 (SCA1), and
spinal bulbar muscular atrophy (SBMA), are caused by
unstable CTG/CAG repeats. Repeat instability in pa-
tients and families has recently been reviewed (Cleary
and Pearson 2003; Pearson 2003). In addition to mu-
tations occurring in the germ line (Pearson 2003), so-
matic repeat expansions during early development have
been observed in fetuses with DM1 (Jansen et al. 1994;
Wohrle et al. 1995; Zatz et al. 1995; Martorell et al.
1997) but not HD or SBMA (Benitez et al. 1995; Jedele
et al. 1998). Only low levels of somatic instability have
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been observed in individuals with HD, SCA1, or SBMA,
and, in the former two, length heterogeneity is restricted
to the brain and sperm (Cleary and Pearson 2003). In
contrast, individuals with DM1 can display high levels
of somatic instability, in which intertissue repeat-length
differences as large as 1,000 repeats are evident during
early fetal development, and differences as great as 3,000
repeats are seen in adult patients (e.g., between either
muscle or skin and the peripheral blood leukocytes of a
given patient with DM1) (Anvret et al. 1993; Thornton
et al. 1994; Wohrle et al. 1995; Zatz et al. 1995; Peterlin
et al. 1996; Martorell et al. 1997). Ongoing expansions
in somatic cells may contribute to the progressive nature
and tissue specificity of disease symptoms (Wong et al.
1995; Martorell et al. 1998).
It is important to understand how repeat expansions
occur in their chromosomal context within patient cells
for the following reasons: First, the mutation and asso-
ciated diseases are unique to humans. Second, disease-
specific cis elements, including flanking sequences (Ne-
ville et al. 1994) and chromatin context, are likely to
“drive” the instability (Cleary et al. 2002; Cleary and
Pearson 2003; Libby et al. 2003). Third, different diseases
display variable levels of repeat instability in different
tissues at various developmental windows (Cleary and
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Pearson 2003). Together, these observations suggest that
different mechanisms of instability might occur among
the different disease loci. Indeed, nonhuman model sys-
tems have suggested that various biological processes can
contribute to CTG/CAG instability, including replication
slippage, the direction of DNA replication fork progres-
sion, Okazaki fragment processing, mismatch repair, gap
repair, double-strand break repair, and recombination
(reviewed by Lahue and Slater 2003; Pearson 2003; Lenz-
meier and Freudenreich 2003). However, in spite of this
information, the mutation mechanism occurring at any
one disease locus in any patient tissue (somatic or germ
cells) is poorly understood (reviewed by Cleary and Pear-
son 2003; Pearson 2003).
Models using cultured human cells have given mixed
results regarding trinucleotide repeat instability. Some
failed to show any instability; in others, the mechanism(s)
of instability was not clear. No repeat instability was
observed in cultured cells from patients with SBMA, HD,
or fragile X (FRAXA) (Benitez et al. 1995; Wohrle et al.
1995; Spiegel et al. 1996). In contrast, proliferation of
fibroblasts, myoblasts, or virally transformed lympho-
blasts in patients with DM1 (Wohrle et al. 1995; Peterlin
et al. 1996; Furling et al. 2001; Khajavi et al. 2001) led
to detectable expansions of the diseased CTG repeat
tract. Transgenic mouse models suggest that there may
not be a simple association of cellular proliferation rate
with CTG instability, but they have not excluded a re-
quirement for proliferation (Lia et al. 1998; Gomes-Pe-
reira et al. 2001). Although data supporting any partic-
ular cellular process were lacking in these cellular studies,
it was generally assumed that repeat expansions arose
through replication errors, which contrasts with recent
observations of instability in nonproliferating tissues in
some of the transgenic mouse models (reviewed by Lahue
and Slater 2003; Pearson 2003).
In an effort to understand the mechanism of chro-
mosomal repeat instability in somatic human cells, we
investigated the requirement of cell proliferation and the
effect of various replication inhibitors on CTG instability
in primary cell cultures derived from patients with DM1
harboring an expanded (CTG)216 on the chromosome 19
background typical of families with DM1 (Neville et al.
1994), as well as a normal (CTG)12 on the other chro-
mosome 19. We demonstrated that CTG expansions oc-
curred only in proliferating cells from patients with DM1
and that agents that affect DNA synthesis but not rep-
lication initiation can specifically modulate the instability
of the expanded DM1 CTG repeat.
Methods
Cells and Cell Culture
A primary fibroblast cell line derived from the skin of
a 22.5-wk female fetus with DM1 that harbored a ma-
ternally inherited repeat tract of (CTG)216, with (CTG)12
on the other allele. Haplotype analysis (not shown) re-
vealed that the expanded allele was on the chromosome
19 background typical of families with DM1 (Neville et
al. 1994). The fibroblastic nature of the cells was de-
termined by immunocytochemically staining positive for
vimentin and negative for cytokeratin, desmin, and neu-
ron filament protein (not shown). Another primary fi-
broblast cell line, derived from the skin of a 76-year-old
woman harboring a heterogeneous CTG expansion at
the DM1 locus, was used for the experiments shown in
figure 6. The use of primary human cell lines reduced
the contribution of altered DNA metabolism (replica-
tion, repair, recombination, and CpG methylation) spe-
cific to virally, chemically, or spontaneously transformed
lines (Oppenheim et al. 1981; Habib et al. 1999; Rhim
2000). Unless otherwise noted, cells were cultured in a
Minimum Essential Medium (Invitrogen) supplemented
with 10% fetal bovine serum (Hyclone) at 37C with
5% CO2, as described elsewhere (Kramer et al. 1996).
Proliferating cells were maintained between 20% and
80% confluence and were passaged by splitting 1:4.
Cells were arrested and maintained in a nonproliferating
state by serum starvation (0.5% serum) or by conflu-
ence-induced contact inhibition (with 10% serum), as
described by Dell’orco (1974). Clonal lines were derived
from single cells isolated from the initial population
through the cloning ring technique (Clarke 1997).
Replication Inhibitors
Mimosine (Sigma) was stored at 20C as a 10 mM
solution in NaOH/PBS, aphidicolin (Sigma) was stored
at20C as a 1 mM stock solution in dimethyl sulfoxide/
PBS, and emetine (Sigma) was stored at 20C as a 1
mM stock solution in PBS. Mimosine concentration was
determined using a range that was previously documented
to inhibit initiation of replication origins (Krude 1999).
Flow cytometry confirmed that the concentration we used
blocked DM1 cells in late G1, prior to replication initi-
ation. Aphidicolin concentration was empirically deter-
mined such that the proliferation of the DM1 cells was
not arrested but cells would replicate slowly (under per-
turbed conditions) in the presence of this polymerase in-
hibitor. Emetine concentration was determined using a
range reported to result in preferential inhibition of lag-
ging strand synthesis (Burhans et al. 1991). We confirmed
by flow cytometry that both aphidicolin and emetine con-
centrations that we used resulted in increased levels of
DM1 cells in S phase, typical of cells with impaired rep-
lication forks. Cells were exposed to replication inhibitors
through use of the regimen that is outlined in figure 2
and is described in detail in the figure legend and the
“Results” section.
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Figure 1 DM1 CTG expansion in cultured DM1 fibroblasts re-
quires cell proliferation. Starting cells (S) were split into control, pro-
liferating cells (P), and growth-arrested cells (Non-Prolif.) regimens.
Growth arrest was induced by serum starvation (0.5% serum, indi-
cated by “0.5”) or by confluence-induced contact inhibition (10%
serum, indicated by “10”). Proliferating cells were split 1:4 nine times
over the 40 d. DNAs were isolated, CTG repeats of the DM1 locus
were PCR amplified (see the “Methods” section), and tract lengths
were determined on 1.5% agarose gels. The size marker has been
converted to repeat numbers. The normal (CTG)12 and expanded dis-
eased (CTG)216 DM1 alleles are indicated. To facilitate comparison,
the control starting and proliferating samples were loaded flanking the
arrested samples.
Repeat-Tract Length Analysis
Genomic DNAs were isolated as described by Kramer
et al. (1996). DM1 CTG tract length analysis was per-
formed as follows. Standard PCRs were performed using
100 ng of genomic DNA in the presence of 0.1 mCi
a[32P]-dCTP and using previously described primers and
amplification conditions (Kramer et al. 1996). Small-
pool PCRs (spPCRs) and their analyses were performed
essentially as described by Monckton et al. (1995), Wong
et al. (1995), and Libby et al. (2003), through use of 1–
10 amplifiable genome equivalents that were empirically
determined by titrations for each genomic sample. As
many as 15–40 spPCRs were performed per sample,
each containing 1–5 products of the expanded allele (fig.
4). Repeat-tract lengths of both standard and spPCR
products were determined relative to a DNA size marker,
after resolution on 1.5% and 1.8% agarose gels, re-
spectively. Sizes were confirmed on denaturing sequenc-
ing gels. Determination of the length from any given
electrophoretic band cannot be absolute, since size res-
olution is limited for the longer DNAs: for standard
PCR, reported fragment sizes were determined from the
peak intensities of individual electrophoretic bands from
six independent experiments, and an average is reported.
The trinucleotide and dinucleotide tract lengths of the
ERDA1, CTG18.1, FRAXA, and Mfd15 loci were PCR
amplified from genomic DNA in the presence of 0.1 mCi
a[32P]-dCTP, through use of primers and amplification
conditions described elsewhere (Fu et al. 1991; Breschel
et al. 1997; Dietmaier et al. 1997; Nakamoto et al.
1997). Products were sized relative to sequencing ladders
after resolution on denaturing 5% polyacrylamide gels,
were dried, and were exposed to x-ray film.
Statistical Analysis
Mann-Whitney tests and SDs were assessed by SPSS
10, and the Fisher’s Exact test was performed through
use of the Fisher’s Exact Test Web site. All of the com-
piled data can be found in appendices A, B, and C (on-
line-only).
Results
Instability Occurs in Proliferating but not Quiescent
DM1 Cells
To determine the requirement of cell proliferation for
repeat instability, we assessed CTG repeat lengths in par-
allel DM1 cell cultures that had been maintained under
proliferative and quiescent states. CTG expansions did
not occur in the absence of cell proliferation. After being
maintained in a nonproliferative state for 40 d, the CTG
tract lengths of both the normal and expanded disease
alleles were unchanged relative to the starting culture
(compare nonproliferating lanes with starting [S] lanes in
fig. 1). In contrast, the proliferating control cells, which
had gone through 18 population doublings (PDs) over
the 40 d, displayed continuous expansions of the disease
allele up to 225 repeats, gaining 9 repeats, whereas the
normal allele, (CTG)12, remained unchanged (compare
proliferating [P] lanes with starting [S] lanes in fig. 1).
Multiple rounds of growth arrest and release did not affect
the rate of CTG expansion relative to the total number
of PDs (data not shown), and there was no significant
variation between CTG length prior to and following
growth arrest (Mann-Whitney ). The absence ofP 1 .05
expansions in the quiescent cells indicated that somatic
instability at the DM1 CTG repeat in cultured human
fibroblasts is mediated by processes active only during
proliferation, possibly during replication.
Growth and Inhibitor-Treatment Strategy
We speculated that insights into the mechanism of
repeat instability could be gained if the exposure of cells
to replication inhibitors known to perturb different as-
Figure 2 Drug treatment and growth of DM1 fibroblasts. A, Strategy of drug treatments. Logarithmically growing cells from the same
initial plate were split into control (no drug) and drug treatment regimens. To avoid selection for drug-resistant lines, cells were repeatedly
exposed to one drug, with drug-free recovery periods between exposures. One “round” of treatment, including exposure and recovery periods,
represented a total of three cell PDs. Cells were maintained between 20% and 80% confluence. Approximately 5–6#105 cells/plate at 40%
confluence (100-mm plates) were exposed to 1 mM emetine or 200 mM mimosine for 18 h, during which the rate of replication progressively
decreased. Low-dose aphidicolin (0.207 mM) exposure spanned a single PD. After exposure, drugs were removed, and cells were washed with
PBS and allowed to recover in fresh, drug-free media. Cells were passed through subsequent treatment/recovery regimens for as many as five
rounds of exposure to the same drug. At the end of each recovery period, an aliquot of cells was removed, and genomic DNA was extracted
for CTG length analyses. For the “no-drug” controls, an equal amount of cells were mock-treated through the same number of cell doublings,
and aliquots were taken for DNA analysis after the same number of PD. B, Proliferative status. Drug exposures occurred between blackened-
to-blackened shapes, and drug-free recovery periods occurred between blackened shapes interspersed with unblackened shapes.
Figure 3 Expansion of chromosomal DM1 CTG repeats in DM1 fibroblasts with or without exposure to replication inhibitors. Control and
drug-treated cells were grown through one to five rounds, as outlined in figure 2, and DNAs were isolated for PCR analysis (see the “Methods”
section). DM1 CTG repeat lengths were determined on 1.5% agarose gels, relative to a DNA size marker (converted to repeat numbers). A, Results
from one set of six independent experiments (experiment #1). PCR products from control cells grown in the absence of drug (starting culture C0,
multiple rounds C1–C5). To facilitate length comparisons, flanking each set of PCR products from drug-treated cells are PCR products from control
cells (C1 or C5). PCR products are from cells treated with mimosine (rounds M1–M5); aphidicolin (rounds A1–A5); and emetine (rounds E1–E5).
B, Summary of the PCR products of fifth round of growth in control, mimosine-, aphidicolin-, and emetine-treated cells from five other independent
sets of experiments. The normal DM1 allele remained at (CTG)12 and, for the sake of clarity, only the upper portion of the gel with the unstable
disease allele is shown. All panels are portions of the same gel, permitting the comparison between all lanes and the starting C0 sample in the first
panel. C, Graphical representation of the sizes of the major diseased CTG products in each fifth round of control and drug-treated samples. For
each sample, individual measurements are unblackened symbols, the mean is blackened, and the error bars show plus and minus one sample SD
of the data. Two major products were observed in two emetine-treated samples (experiments #4 and #6); hence, there are eight data points for the
six repetitions of the experiment. The four emetine-treated samples that displayed synchronous expansions (experiments #1 #2, #3, and #5) are
separated out plotted to the right (“Synch.”). The complete sizing of these samples can be found in appendix A (online only).
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pects of DNA synthesis were to alter repeat instability.
We selected inhibitors for which the mechanism of action
is well characterized. Mimosine inhibits replication in-
itiation in human cells (Krude 1999). Aphidicolin in-
hibits DNA polymerases a, d, and e, which act on both
the leading and lagging strands of replication forks, as
well as at sites of DNA repair (Wright et al. 1994; Mi-
chael et al. 2000). Emetine induces imbalanced synthesis
at chromosomal replication forks, preferentially block-
ing synthesis of Okazaki fragments on the lagging strand
but not on the leading strand (Burhans et al. 1991).
Synthesis of only the leading strand results in replication
forks with long stretches of single-stranded lagging
strand template. Thus, each drug affected different as-
pects of DNA metabolism that may participate in CTG
instability.
The basic strategy for inducing repeat-length altera-
tions is outlined in figure 2A. Logarithmically growing
cells from the same initial plate were split into control
(i.e., no drug) and drug treatment regimens. To avoid
selection for drug-resistant lines, cells were repeatedly
exposed to only one drug, with drug-free recovery pe-
riods between treatments. One “round” of treatment
included a drug exposure and a recovery period, rep-
resenting a total of three cell PDs. Cells were exposed
to 200 mM mimosine or 1 mM emetine for 18 h, during
which the rate of replication progressively decreased un-
til it was completely arrested. Low-dose aphidicolin
(0.207 mM) exposure did not completely arrest repli-
cation, but it did slow growth, and exposure spanned a
single PD. After exposure, drugs were removed and cells
were allowed to recover. Cells were passed through sub-
sequent treatment/recovery regimens for as many as five
rounds. At the end of each round, an aliquot of cells
was removed and genomic DNA extracted for CTG
length analysis. For the “no-drug” controls, cells were
mock treated and aliquots were taken for DNA analysis
after the same number of PDs. Treating cells with drugs
multiple times permitted monitoring of the CTG tract
for possible length alterations over a time course.
The effect of each drug on cell growth was monitored
through multiple rounds of treatment. As noted above,
an 18-h exposure to either mimosine or emetine had a
considerable affect on cell growth, whereas low-dose
aphidicolin exposure only slowed proliferation, extending
the PD time (fig. 2B). The inhibitory effects of each drug
were reversible, and, for a given drug, the growth rate
between individual treatments was consistent. Treated
cells continued to be sensitive to the inhibitory action of
the drug with subsequent treatments, indicating that we
had not selected for drug-resistant populations.
Spontaneous CTG Expansions Can Be Modulated
In the absence of a drug, continued expansions of only
the diseased DM1 (CTG)216 repeat occurred over mul-
tiple PDs (fig. 3A, control: compare lanes C1–C5). The
normal allele remained (CTG)12. Expansions appeared
to be “synchronous,” in that the majority—if not all—
of the DM1 alleles in the population of cells seemed to
expand together, permitting these expansions to be de-
tected using standard PCR techniques (see the “Meth-
ods” section). This experiment was repeated as many as
six times, and a summary of the fifth rounds of growth
in control cells is shown in figure 3B (control). Figure
3C shows a graphical representation of the sizes of the
major diseased CTG products in each fifth-round sam-
ple. Over the course of five rounds of growth, the dis-
eased allele increased significantly, by 7–10 repeats/15
PDs, to an average length of repeats (Mann-224 1.2
Whitney ) (see controls in fig. 3A, 3B, and 3C).Pp .002
Similar “synchronous” CTG expansions of comparable
magnitudes were reported in DM1 fibroblasts (Wohrle
et al. 1995; Peterlin et al. 1996) and myoblasts (Furling
et al. 2001) but not in Epstein-Barr virus–transformed
lymphoblasts (Khajavi et al. 2001).
Inhibition of replication initiation with mimosine
yielded CTG expansions similar to those in control cells
(fig. 3A, mimosine). As assessed from a total of six in-
dependent experiments (fig. 3B, mimosine), five expo-
sures to mimosine did not cause a significant change in
the level of CTG instability (Mann-Whitney ),Pp .093
resulting in a mean size of repeats, similar to226 1.5
the repeats in control cells (fig. 3C). Thus,224 1.2
repeated inhibition of replication initiation by mimosine
had little or no effect on CTG instability. This obser-
vation is similar to the lack of an effect by growth arrest
in G0 by serum starvation (see fig. 1).
Inhibition of both leading and lagging strands of rep-
lication forks by aphidicolin enhanced the magnitude of
CTG expansion relative to that in control cells. Aphi-
dicolin induced continued synchronous expansions over
multiple treatments, displaying an increased number of
CTG repeats gained relative to cells grown in the absence
of drug for the same number of PDs (fig. 3A, aphidicolin:
compare lanes A1–A5 with C1 and C5). The enhancing
effect of aphidicolin upon CTG expansions was highly
reproducible over six identical experiments, inducing ex-
pansions to a final mean size of repeats (fig.235 2.1
3B, aphidicolin). Aphidicolin led to gains of 16–21 re-
peats/15 PDs, which were significantly greater than the
7–10 repeats/15 PDs gained in control cells, representing
a two- to threefold increase (Mann-Whitney )Pp .002
(fig. 3C). Aphidicolin affected the stability of only the
expanded allele, while the normal DM1 allele remained
(CTG)12.
The preferential inhibition of lagging-strand synthesis
by emetine had two distinct effects on the expanded
CTG tract, in that it enhanced CTG expansions and also
perturbed the apparent synchronous nature of the ex-
pansions. The latter effect manifested as an increased
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Figure 4 spPCR analysis of the DM1 CTG tract from control,
aphidicolin-treated, and emetine-treated cells. As many as 15–40 in-
dividual spPCRs per sample were performed (see the “Methods” sec-
tion), and CTG lengths of each product in each reaction were deter-
mined on 1.8% agarose gels, relative to a DNA size marker (converted
to repeat numbers). A, A representative set of spPCR products from
the first and fifth rounds of growth of control cells (in the absence of
inhibitors) and from the fifth round of growth in the presence of aphi-
dicolin or emetine. The normal DM1 allele remained (CTG)12, and,
for the sake of clarity, only the upper portion of the gel with the
unstable disease allele is shown. B, Graphical representation of CTG
size distributions of individual spPCR products in each sample. To
facilitate comparisons, a dashed line indicates the peak CTG size in
the fifth round of control cells (C5). The complete sizing and analysis
of these and other samples can be found in appendix B (online only).
degree of CTG length heterogeneity, evidenced by both
the broad, nondistinct nature of the major products and
the occurrence of multiple major products (fig. 3B, em-
etine). In four independent experiments, emetine induced
continuous expansions over the multiple treatments rel-
ative to control cells grown for the same number of PDs
(fig. 3A, emetine: compare lanes E1–E5 with C1 and C5;
fig. 3B, emetine: experiments #2, #3, and #5). In these
four experiments, emetine significantly enhanced CTG
expansions relative to control cells to a broad range of
final sizes, with a mean of repeats (note the236 9.8
large SD) (Mann-Whitney ) (fig. 3C, E5 syn-Pp .01
chronous experiments). This represents an average gain
of 20 repeats/15 PDs, which is a two- to threefold in-
crease over the 7–10 repeats/15 PDs gained by control
cells. In two separate experiments, more than one major
product was observed (fig. 3B, emetine: experiments #4
and #6). The lower expanded allele in these samples may
have arisen by the selection of cells in the starting pop-
ulation with that length, since their sizes were not sig-
nificantly different from those in the controls (Mann-
Whitney ). Both the enhanced expansions andPp .071
the increased CTG length heterogeneity caused by em-
etine treatment in each experiment were further assessed
by an independent and more sensitive assay (below).
spPCR Analysis Reveals Frequency and Magnitude
of CTG Length Alterations
Analysis using the highly sensitive spPCR assay re-
vealed that significantly greater expansions were induced
by aphidicolin and emetine; it also indicated the full
range of repeat lengths within control and drug-treated
samples. spPCR permits the sizing of individual CTG
alleles within the population and facilitates the detection
of rare large expansion and deletion events, thereby pro-
viding an accurate representation of the CTG length dis-
tribution within a sample (Monckton et al. 1995; Wong
et al. 1995; Libby et al. 2003). Representative spPCR
products of DNAs from the control, aphidicolin-treated,
and emetine-treated cells are shown in figure 4A, and a
graphic representation of the CTG size distributions is
shown in figure 4B. In control cells, after five rounds of
growth in the absence of drug, the distribution of CTG
sizes was significantly increased (Mann-Whitney P !
), with the mean shifting from 205 repeats (C1) to.001
222 repeats (C5) and with sizes in the fifth round ranging
from 171 to 257 repeats (compare C1 with C5 in fig.
4B). The majority of alleles shifted from a range of 201–
220 repeats (C1) to 221–240 repeats (C5), confirming
the synchronous nature of the expansions. The CTG size
in the aphidicolin-treated cells was significantly greater
than in control cells (Mann-Whitney ), havingPp .001
a mean of 236 repeats, with sizes ranging from 159 to
338 repeats (compare A5 with C5 in fig. 4B). In four of
the emetine-treated samples, the mean size of the CTG
repeat was significantly greater relative to that in the
control cells (Mann-Whitney P ranging from !.001 to
.002) and ranged from 107 to 386 repeats (compare E5
with C5 in fig. 4B). In the two emetine-treated samples
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Figure 5 Preferential and actively enhanced expansions of the
diseased DM1 CTG repeat. A, Repeat-tract lengths of the ERDA1,
CTG18.1, FRAXA, and Mfd15 loci were determined by PCR (see the
“Methods” section) in control and drug-treated DM1 cells grown
through one to five rounds, as outlined in figure 2. DNAs were isolated
for PCR analysis (see the “Methods” section), and tract lengths were
determined on denaturing 5% polyacrylamide gels, relative to se-
quencing ladders. Only the first and fifth rounds of the control and
emetine-treated cells are shown. The same analysis was performed on
DNA from aphidicolin-treated and mimosine-treated cells; length var-
iation was not observed at any of these repeats (data not shown). B,
Expansion of DM1 CTG repeats in a single cell clonal line of the DM1
fibroblasts. Control and drug-treated cells were grown through mul-
tiple rounds, and DNAs were isolated as outlined in figure 2A. DM1
CTG repeats were PCR amplified, and tract lengths were determined
by electrophoresis on 1.5% agarose gels alongside a DNA size marker
(converted to repeat numbers). To facilitate length comparisons, flank-
ing each set of PCR products from drug-treated cells are PCR products
from control cells (C1 or C3). Although this gel was run at a slant,
CTG length differences are observable by comparing flanking C3 with
E3 or A3 (compare lanes indicated by asterisks with those indicated
by triangles). As indicated, shown are PCR products from control cells
grown in the absence of drug (rounds C1–C3), cells treated with em-
etine (rounds E1–E3), aphidicolin (rounds A1–A3), or mimosine
(rounds M1–M3).
that displayed more than one major expanded allele by
standard PCR (fig. 3B, emetine: experiments #4 and #6),
the mean CTG size by spPCR was 237 repeats (not
shown) and 228 repeats (not shown). Although greater
than the mean size in the control (222 repeats), these
were not significantly different (Mann-Whitney Pp
and ). In all six emetine-treated samples,.076 Pp .32
the range of CTG tract lengths (107–386 repeats) was
considerably greater than that in control cells (171–257
repeats). Importantly, in the emetine-treated samples, a
significant portion of alleles (25%) contained more re-
peats (as many as 129 more) than the largest tract,
(CTG)257, observed in the control cells (Fisher’s Exact
test, two-tailed ), representing gains of as manyP ! .001
as 170 repeats onto the initial (CTG)216. In contrast, only
1% of emetine-treated alleles contained fewer repeats
than the shortest tract, (CTG)171, in the control, and
these were not significant (Fisher’s Exact test, two-tailed
). Similarly, for aphidicolin-treated samples, 11%Pp 1
of the alleles were significantly larger (as many as 81
repeats) than the largest tract, (CTG)257, in the controls
(Fisher’s Exact test, two-tailed ), which rep-Pp .038
resents 122 repeats more than the initial (CTG)216, and
only a nonsignificant 2% contained fewer repeats than
the shortest tract, (CTG)171, in the control samples
(Fisher’s Exact test, two-tailed ). Thus, aphidicolinPp 1
and emetine enhanced both the CTG expansion size and
CTG tract length heterogeneity.
Specificity of Inhibitor-Induced Instability
The preferential susceptibility of the expanded—but
not the normal—DM1 allele to mutations induced by
replication fork inhibitors was further investigated by
analyzing other repeat loci (ERDA1, CTG18.1, FRAXA,
and Mfd15) in DNAs derived from mimosine-treated,
aphidicolin-treated, and emetine-treated DM1 cells, as
well as control cells. Although these repeat tracts can
display length instabilities in some individuals and can
be hypersensitive to changes in repair-deficient cells (Fu
et al. 1991; Breschel et al. 1997; Dietmaier et al. 1997;
Nakamoto et al. 1997), none of the short tracts varied
in length after multiple exposures to emetine (fig. 5A)
or mimosine or aphidicolin (data not shown). These re-
sults illustrate that aphidicolin and emetine preferen-
tially affected the stability of the expanded disease DM1
CTG tract in the fibroblasts of patients with DM1.
Active Expansions Occur in a Single Cell Clone
To determine whether the progressively larger alleles
observed were due to active repeat expansion or were
solely the result of selective growth of a few cells con-
taining longer repeats, we isolated a clonal line of the
DM1 cells and subjected it to the drug treatment regi-
men. Since the clonal line was derived from a single cell,
it permitted any alleles with repeat lengths different from
those of the progenitor cell to be scored as mutants.
Similar to the mixed population, both spontaneous and
drug-enhanced CTG expansions were observed in the
clonal lines. The pattern of CTG expansion appeared
synchronous. Repeated treatments with emetine or aphi-
dicolin resulted in progressively larger DM1 CTG tracts
(compare lanes C1–C3 with E1–E3 and A1–A3 in fig.
5B). Mimosine failed to alter the magnitudes of expan-
sion (compare lane M3 with C3). The extensive growth
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required for isolation of the clonal lines from single cells
reduced the growth potential of the cells, which may be
related to the reduced culture life previously reported
for DM1 cells (Furling et al. 2001; Khajavi et al. 2001).
Multiple experiments from different clones consistently
showed spontaneous expansions that were enhanced by
emetine and aphidicolin treatment but not by mimosine
treatment. Other experiments revealed that, after treat-
ment, the enhanced expansion rate did not persist with-
out subsequent drug treatments, revealing that we had
not selected for a subpopulation with an inherently in-
creased expansion rate (not shown). Thus, active ex-
pansions are occurring in the fibroblasts. In addition to
active expansions, selective growth advantage of daugh-
ter cells with de novo expansion may also be occurring
in our cell cultures. Together, the results indicate that
active expansions of the DM1 CTG repeat are sponta-
neously occurring and that emetine or aphidicolin treat-
ment enhanced the magnitude of the expansions.
Spontaneous CTG Expansions Can Be Modulated
in an Adult DM1 Cell Line
An independent cell line derived from the skin of an
adult patient with DM1 was subjected to the same
growth/treatment regimen, to determine the effect of rep-
lication inhibitors, since the pattern of CTG expansions
in cultured DM1 cells can vary. The synchronous ap-
pearance of the CTG expansions in fetal cell lines ob-
served by us and by others (Wohrle et al. 1995; Furling
et al. 2001) may be due to the low levels of intratissue
CTG length heterogeneity acquired at this early stage
(instability is first detectable around week 16 of fetal
development) (Wohrle et al. 1995; Martorell et al. 1997).
High levels of intratissue CTG length heterogeneity in
adult patients with DM1 are age-dependent (Wong et
al. 1995; Martorell et al. 1998). Although cultured cell
lines derived from adult patients with DM1 display ac-
tive CTG expansions, the pattern was not synchronous
(Ashizawa et al. 1996; Khajavi et al. 2001). We extended
our experiments to an adult (76 year old) fibroblast cell
line. Unlike the fetal line, the adult line displayed con-
siderable CTG length heterogeneity, which is consistent
with the age dependency of heterogeneity (Wong et al.
1995). The majority of the cells had CTG tracts ranging
from 63 to 241 repeats (fig. 6A: see disease allele pop-
ulation 1), and a minor population had larger repeat
sizes (fig. 6A: see disease allele population 2 and bands
on C1 lanes indicated by arrows). The degree and mag-
nitude of CTG length heterogeneity was confirmed by
isolation of individual clones, which contained only one
expanded allele from either size population. Unfortu-
nately, these clonal lines did not have sufficient growth
potential for further experimentation (data not shown).
After growth in drug-free conditions, two major pop-
ulations of CTG lengths became apparent: those with
lengths ranging from 56 to 260 repeats and those rang-
ing from 295 to 570 repeats (compare C1–C5 in fig.
6A). The increase in cells with longer repeats indicates
a “mitotic drive,” or selective growth advantage of cells
with longer tract lengths, a phenomenon previously de-
scribed for cultured lymphoblastoid cells from adults
with DM1 and transgenic mouse cells (Gomes-Pereira
et al. 2001; Khajavi et al. 2001). Active spontaneous
CTG expansions were also occurring, since the CTG
distribution in C5 cells was significantly larger than that
in C1 cells (Mann-Whitney ) (compare C1 withP ! .001
C5 in fig. 6C). Importantly, in the C5 samples, a sig-
nificant portion of alleles (8%) contained more repeats
(as many as 25 more) than the largest tract, (CTG)545,
observed in the C1 cells (Fisher’s Exact test, two-tailed
). Multiple treatments with aphidicolin or em-Pp .001
etine significantly enhanced the magnitude of CTG ex-
pansions (compare C5 with A5 and C5 with E5 in fig.
6B; see also fig. 6C). The CTG size in the aphidicolin-
treated cells was significantly greater than in control cells
(Mann-Whitney ) and contained a significantPp .007
portion of alleles (10%) with more repeats (as many as
152 more) than the largest tract, (CTG)570, observed in
the C5 cells (Fisher’s Exact test, two-tailed )P ! .001
(compare A5 with C5 in fig. 6C). Similarly, the CTG
size in the emetine-treated cells was significantly greater
than in control cells (Mann-Whitney ) and con-P ! .001
tained a significant portion of alleles (13%) with more
repeats (as many as 207 more) than the largest (CTG)570
tract observed in the C5 cells (Fisher’s Exact test, two-
tailed ) (compare E5 with C5 in fig. 6C). UnderP ! .001
all conditions, the normal CTG allele did not change
(fig. 6A and 6B). These results provide independent ev-
idence that spontaneous CTG expansions are occurring
at the DM1 disease locus and that the magnitude of these
expansions is enhanced by treatment with either aphi-
dicolin or emetine.
Discussion
Of the 14 diseases associated with CTG/CAG expansions,
the contribution of somatic instability is most predomi-
nant for DM1, in which large intertissue repeat-length
differences are evident during early fetal development and
in adult patients (Wohrle et al. 1995; Zatz et al. 1995;
Martorell et al. 1997). Considerably greater expansions
have been observed in muscle (Anvret et al. 1993; Thorn-
ton et al. 1994), fibroblasts, and skin (Peterlin et al. 1996)
than in blood from the same individual with DM1. In
blood, CTG expansions can continue throughout the life
of affected individuals (Wong et al. 1995; Martorell et al.
1998), although the same may not be true for muscle
(Anvret et al. 1993; Thornton et al. 1994). It has been
suggested that, in muscle and fibroblasts, expansions be-
Figure 6 spPCR analysis of the DM1 CTG tract from an adult cell line. As many as 40 individual spPCRs per sample were performed
(see the “Methods” section), and CTG lengths of each product in each reaction were determined on 1.8% agarose gels relative to a DNA size
marker (converted to repeat numbers). A, A representative set of spPCR products from the first, second, third, fourth, and fifth rounds of
growth of control cells grown in the absence of inhibitors (C1–C5). The major and minor populations of cells harboring shorter and longer
CTG expansions are indicated as “population 1” and “population 2,” respectively. Individual faint products in population 2 of C1 are indicated
by arrows. B, A representative set of spPCR products from the fifth round of growth in the absence (C5) or presence of aphidicolin (A5) or
emetine (E5). Panels A and B are portions of the same gel, permitting the comparison between all lanes and the starting C1 samples. C, Graphical
representation of CTG size distributions of individual spPCR products in each sample. The complete sizing and analysis of these and other
samples can be found in appendix C (online only).
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gin during early development, progress during cell divi-
sion, and cease in childhood at a stage coincident with
cell quiescence and terminal differentiation (Zatz et al.
1995). Larger CTG expansions in tumors of patients with
DM1 relative to their nonneoplastic tissue suggest that
expansions may also occur during acquired cell prolif-
eration (Osanai et al. 2000; Kinoshita et al. 2002). We
have experimentally demonstrated that somatic CTG in-
stability at the DM1 locus is mediated by processes that
are functional in proliferating cells and that cell quiescence
is associated with the arrest of expansions.
Active expansions of the DM1 CTG repeat occurred
spontaneously in cultured DM1 fibroblasts. The ap-
parent “synchronous” pattern has been reported for
various cultured DM1 fetal cells from different tissues
(Wohrle et al. 1995; Furling et al. 2001). spPCR re-
vealed that the changes were not strictly synchronous
but that the range of expansion sizes was limited. The
pattern of synchronous expansion is unusual and, for
no obvious reason, it seems that the magnitude of re-
peats gained by most cells was similar. This may reflect
the amount of excess or slipped repeats that are per-
mitted within the replication fork machinery. Although
we have demonstrated that active expansions are oc-
curring, selective growth advantage of cells harboring
larger repeats may also be operating, particularly after
considerable length heterogeneity has been established,
as may be evident in older patients. The mode of CTG
expansion observed herein may resemble instability oc-
curring in somatic tissues of fetuses and patients with
DM1.
Aphidicolin and emetine enhanced the magnitude of
CTG expansions in DM1 fibroblasts. Both compounds
act on replication forks but do not damage DNA, sup-
porting a mechanism of somatic expansion involving
replication forks. Aphidicolin, but not emetine, can in-
duce locus-specific “common” but not “rare” fragile
sites (Sutherland and Richards 1999). Rare fragile sites,
such as FRAXA, are induced by folate perturbations
but not by aphidicolin. It is unlikely that the enhanced
DM1 CTG expansion is related to fragile-site expres-
sion, since none of the sequenced common fragile sites
contain repeated sequences. Furthermore, numerous
stressors, including aphidicolin, have failed to induce
fragile-site expression at the DM1 locus in normal or
patient cells (Jalal et al. 1993; Wenger et al. 1996), and
the DM1 region is not predisposed to breakage or re-
combination, which are common to many fragile sites.
Thus, aphidicolin- and emetine-enhanced CTG expan-
sions are likely mediated by mutagenic events at the
replication fork.
We demonstrated that CTG expansions occurred only
in proliferating cells from patients with DM1 and that
agents that affect DNA synthesis—but not replication
initiation—can specifically modulate the instability of the
expanded DM1 CTG repeat. Our results may reflect re-
peat expansions occurring either by repair processes that
are replication-independent but active only during cell
proliferation or by the formation and error-prone pro-
cessing of replication fork errors. Several pieces of evi-
dence favor the latter possibility. First, the fact that many
repair processes, including mismatch repair, are active in
both proliferating and quiescent cells argues against a
proliferation-specific repair mechanism (Dell’orco and
Whittle 1978; reviewed by Nouspikel and Hanawalt
2002). Second, the increased expansions induced by aphi-
dicolin and emetine likely arose through their pertur-
bation of replication forks rather than by repair pro-
cesses, since protein-synthesis inhibitors such as emetine
preferentially affect replication (Gautschi et al. 1973; Sti-
mac et al. 1977), and aphidicolin does not affect all forms
of repair (Wright et al. 1994; Wood and Shivji 1997).
Third, the lack of an effect by mimosine, which can also
affect repair, supports replication-mediated expansions.
Fourth, since neither aphidicolin nor emetine is known
to directly damage DNA, it is unlikely that their effect
on CTG instability arose from damage-induced, error-
prone repair. Thus, our data support a mechanism of
somatic DM1 CTG expansions occurring by replication
fork errors.
We propose that aphidicolin or emetine induced im-
balanced DNA synthesis between the leading and lagging
strands and thereby facilitated CTG expansions. The em-
etine-enhanced CTG expansions were likely mediated by
the striking effects of this compound upon replication
fork dynamics, permitting considerable stretches of lead-
ing-strand synthesis in the complete absence of lagging-
strand synthesis (Burhans et al. 1991). Different poly-
merases might participate in the polymerization and/or
exonucleolytic steps of leading- and lagging-strand syn-
thesis (e.g., polymerases a, d, and e) (Karthikeyan et al.
2000; Sogo et al. 2002; Chilkova et al. 2003). The dif-
ferential inhibition of these polymerases by a low dose
of aphidicolin (Wright et al. 1994) might induce un-
coupling of leading- from lagging-strand synthesis,
thereby facilitating expansions. Both aphidicolin and em-
etine induce extensive regions of single-stranded template
DNA at replication forks (Burhans et al. 1991; Michael
et al. 2000). Biophysical destabilization of replication
forks may occur preferentially at expanded repeat tracts
and could facilitate genetic instability, possibly involving
slipped-strand DNAs (Pearson et al. 2002). Perturbation
of replication fork dynamics by either emetine or aphi-
dicolin enhanced by threefold the magnitude of short
expansions in most cells, whereas 11%–25% of cells ex-
perienced gains of 122–170 repeats (from [CTG]216 to
[CTG]338–[CTG]386). Consistent with a replication-based
mechanism are the observations that treatment of mam-
malian cells with various replication inhibitors induced
overreplication and gene amplification (Hoy et al. 1987),
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as well as increased replication fork-associated recom-
bination between tandem repeats (Saintigny et al. 2001).
Recent evidence from model systems indicates the im-
portance of replication fork dynamics in replication-me-
diated CTG instability (Samadashwily et al. 1997; Cleary
et al. 2002; reviewed by Lahue and Slater 2003; Lenz-
meier and Freudenreich 2003). The results presented here
show that CTG expansions at a disease chromosomal
locus (DM1) in patient cells occur through replication
errors. Our results support replication-mediated CTG ex-
pansions at the DM1 chromosomal locus.
Regardless of the precise mechanism, we have dem-
onstrated that exposure to exogenously added com-
pounds can specifically alter the genetic instability of
the expanded CTG tract at the DM1 chromosomal lo-
cus in patient cells, leaving the normal DM1 allele and
other sequences unaffected. The longer expanded CTG
tract at the diseased allele may be hypermutable when
replication is impaired by inhibitors, a sensitivity that
may be mediated by an increased propensity to form
slipped-strand DNA structures, which are known to be
sensitive to repeat length (Pearson et al. 2002). This
interpretation is consistent with the enhanced expan-
sions being caused by perturbation of replication fork
progression but not by the inhibition of replication in-
itiation or by the ablation of instability with the arrest
of proliferation. We suggest that the mode through
which the DM1 chromosomal CTG repeat is replicated
is a critical determinant of repeat instability, and com-
pounds that alter this replication may critically affect
the fidelity by which the CTG repeats are copied. The
identification of exogenously added compounds that
specifically alter repeat instability at a disease locus pro-
vides insight for research aimed at developing phar-
macological agents that would intervene with the mu-
tation process, to slow pathogenesis in humans.
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